Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026
Cision•28/10/2026•06:00 ET
0
Key Highlights
- ➤Leqembi sales reached JPY 32.2 billion in Q3 2026
- ➤BioArctic royalty rose approximately 74% year over year to SEK 203.8 million
- ➤BioArctic will publish its Q3 2026 report November 25, 2026
BioArctic Stockholm, Sweden, October 28, 2026 - BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 32.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 203.8 million, which is an increase of approximately 74 percent compared to the royalty recorded by BioArctic for the third quarter of 2025.
BioArctic's report for the third quarter of 2026 will be published on November 25, 2026, at 08:00 am CET.
Get started
Create a free account to read the full story.